Novo Nordisk A/S (NVO) Stock Analysis
A live, multi-source view of Novo Nordisk A/S (NVO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Sector: Healthcare · Industry: Drug Manufacturers - General · Denmark · 66,700 employees · novonordisk.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Novo Nordisk A/S (NVO) had a market capitalization of $206.02B, a trailing P/E of 11.4 (forward 13.6), a dividend yield of 3.78% and a beta of 0.34; the shares traded in a 52-week range of $35.12 – $64.16 (-14.1% over the year).
- Market cap
- $206.02B
- Enterprise value
- $301.49B
- Trailing P/E
- 11.4
- Forward P/E
- 13.6
- PEG ratio
- 3.36
- Price / book
- 6.02
- EPS (trailing)
- $4.07
- EPS (forward)
- $3.42
- Dividend yield
- 3.78%
- Payout ratio
- 44.5%
- Ex-dividend date
- 2026-08-17
- 52-week range
- $35.12 – $64.16
- 52-week change
- -14.1%
- Beta
- 0.34
- Average volume
- 12.0M
- Shares outstanding
- 3.35B
- Short % of float
- 1.07%
- Profit margin
- 35.3%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Novo Nordisk A/S (NVO) last closed at $44.01 (the last completed close before that scan).
Technicals at the scan: RSI 39 (neutral territory), price -4.6% versus its 20-day average, 20-day versus 50-day average spread -3.3%, MACD histogram -0.17.
Sentiment inputs: 64% of recent Finnhub-scored headlines read bullish; StockTwits 89% bullish; Reddit mentions -50% over 24 hours; analyst consensus score 54/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of NVO; corporate insiders filed 0 buys and 0 sells (1 filer, latest disclosure 2026-07-21). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Alan Armstrong (1B/0S). Who is trading what
RapidTradeView pick record
NVO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Novo Nordisk A/S (NVO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NVO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.